Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Brief: Effector Therapeutics Reports Positive Interim Results In Zotatifin Phase 1/2 Clinical Trial

June 5 (Reuters) - eFFECTOR Therapeutics Inc  EFTR.O :
    * POSITIVE INTERIM RESULTS IN ZOTATIFIN (EFT226) PHASE 1/2
CLINICAL TRIAL SHOWING SAFETY AND TOLERABILITY,
    * TWO PARTIAL RESPONSES OBSERVED IN HEAVILY PRE-TREATED ER+
BREAST
CANCER PATIENTS
    * EFFECTOR THERAPEUTICS - TREATMENT EMERGENT ADVERSE EVENTS
(TEAES) RELATED TO ZOTATIFIN WERE MOSTLY MILD, READILY MANAGED
AND REVERSIBLE
    * ANTICIPATE REPORTING TOPLINE DATA FROM OUR CURRENT
EXPANSION
COHORTS BY END OF 2022

Source text for Eikon:  ID:nGNXYzPYM 
Further company coverage:  EFTR.O 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Effector Therapeutics

See all news